Immunotherapy of allergy: Anergy, deletion, and immune deviation

Current Opinion in Immunology

Volumn 10, Issue 6, 1998, Pages 640-645

  Rolland, Jennifer ^a   O'Hehir, Robyn ^b  

^a MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

^b ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EPITOPE; GAMMA INTERFERON; INTERLEUKIN 4; PHOSPHOLIPASE A2;

ALLERGY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CELL PROLIFERATION; CLONAL ANERGY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; T LYMPHOCYTE;

EID: 0032401770     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(98)80082-4     Document Type: Article

References (53)

1. Anonymous Specific allergen immunotherapy for asthma. A position paper of the Thoracic Society of Australia and New Zealand and the Australasian Society of Clinical Immunology and Allergy. Med J Australia. 167:1997;540-544.
2. O'Hehir RE, Garman RD, Greenstein JL, Lamb JR. The specificity and regulation of T-cell responsiveness to allergens. Annu Rev Immunol. 9:1991;67-95.
3. Blaher B, McCluskey J, Puy R, Czarny D, Rolland JM. T cell response to grass pollen allergens: correlation with skin test reactivity and serum IgE levels. Immun Cell Biol. 73:1995;17-22.
4. Li Y, Simons ER, Jay FT, Hay-Glass KT. Allergen-driven limiting dilution analysis of human IL-4 and IFN-γ production in allergic rhinitis and clinically tolerant individuals. Int Immunol. 8:1996;897-904.
5. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-γ secretion in specific allergen-stimulated T cell cultures. J Immunol. 154:1995;4187-4194.
6. Bellinghausen I, Metz G, Enk AH, Christmann S, Knop J, Saloga J. Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol. 27:1997;1131-1139.
7. Akoum H, Tsicopoulos A, Vorng H, Wallaert B, Dessaint JP, Joseph M, Hamid Q, Tonnel AB. Venom immunotherapy modulates interleukin-4 and interferon-γ messenger RNA expression of peripheral T lymphocytes. Immunology. 87:1996;593-598.
8. 2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest. 98:1996;1676-1683.
9. 2-derived peptides by conventional bee venom immunotherapy. J Allerg Clin Immunol. 100:1997;96-103.
10. McHugh SM, Deighton J, Stewart AG, Lachmann PJ, Ewan PW. Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Experiment Allergy. 25:1995;828-838.
11. + regulatory cells or for changes in T cell repertoire.
12. Giannarini L, Maggi E. Decrease of allergen-specific T-cell response induced by local nasal immunotherapy. Clin Experiment Allergy. 28:1997;404-412.
13. + T cells from allergic individuals. J Exp Med. 178:1993;2123-2130.
14. O'Brien RM, Byron KA, Varigos GA, Thomas WR. House dust mite immunotherapy results in a decrease in Der p 2-specific IFN-γ and IL-4 expression by circulating T lymphocytes. Clin Exp Allergy. 27:1997;46-51.
15. + T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-γ J Allerg Clin Immunol. 97:1996;1356-1365.
16. Hakansson L, Heinrich C, Rak S, Venge P. Activation of B-lymphocytes during pollen season. Effect of immunotherapy. Clin Experiment Allergy. 28:1998;791-798.
17. Chen Y, Inobe JI, Marks R, Gonnella P, Kuchroo VK, Weiner HL. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature. 376:1995;177-180.
18. Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldmann M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza haemagglutinin. J Exp Med. 157:1983;1434-1447.
19. Fasler S, Aversa G, Terr A, Thestrup-Pedersen K, de Vries JE, Yssel H. Peptide-induced anergy in allergen-specific human Th2 cells results in lack of cytokine production and B cell help for IgE synthesis. J Immunol. 155:1995;4199-4206.
20. O'Hehir RE, Yssel H, Verma S, de Vries JE, Spits H, Lamb JR. Clonal analysis of differential lymphokine production in peptide and superantigen induced T cell anergy. Int Immunol. 3:1991;819-826.
21. + T cells but later by monocytes and B cells.
22. 2) in the culture.
23. + T cell differentiation. J Immunol. 159:1997;5956-5963.
24. + T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J Exp Med. 181:1995;1081-1089.
25. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 80:1995;707-718.
26. Hathcock KS, Pucilla LG, Linsley P, Hodes RJ. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med. 180:1994;631-640.
27. Perez V, Van PL, Biuckians A, Zheng X, Strom T, Abbas A. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity. 6:1997;411-417.
28. + cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allerg Clin Immunol. 99:1997;254-260.
29. Smith W, Sly PD. Immunotherapy - anergy, deviation or suppression? Clin Experiment Allergy. 28:1998;911-916.
30. Matsuoka T, Kohrogi H, Ando M, Nishimura Y, Matsushita S. Altered TCR ligands affect antigen-presenting cell responses: up-regulation of IL-12 by an analogue peptide. J Immun. 157:1996;4837-4843.
31. Kelso A. Cytokines: principles and prospects. Immun Cell Biol. 76:1998;300-317.
32. Nakamura T, Lee RK, Nam SY, Podack ER, Bottomly K, Flavell RA. Roles of IL-4 and IFN-gamma in stabilizing the T helper cell type 1 and 2 phenotype. J Immunol. 158:1997;2648-2653.
33. Rocklin RE, Sheffer AL, Greineder DK, Meimon KL. Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med. 302:1980;1213-1219.
34. + cells.
35. Mark PG, Segal DB, Dallaire ML, Garman RD. Human T and B cell immune responses to FeI d 1 in cat-allergic and non-cat-allergic subjects. Clin Experiment Allergy. 26:1996;1316-1328.
36. Hoyne GF, O'Hehir RE, Wraith DC, Thomas WR, Lamb JR. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med. 178:1993;1783-1788.
37. Lake RA, O'Hehir RE, Verhoef A, Lamb JR. CD28 mRNA rapidly decays when activated T cells are functionally anergized with specific peptide. Int Immunol. 5:1993;461-466.
38. Schwartz RH. T cell clonal anergy. Curr Opin Immunol. 9:1997;351-357.
39. lck and ZAP-70 tyrosine kinase activities. of special interest J Immunol. 159:1997;53-60 This paper shows that allergen-induced anergy of Th2 cells is associated with defective transmembrane signaling through the TCR.
40. + T cells precedes the development of tolerance in vivo. Int Immunol. 8:1996;335-342.
41. + T cells in downregulating T cell responses to minor epitopes that are found on the same molecule as the immunodominant T cell anergen.
42. Lowrey JA, Savage NDL, Palliser D, Corsin-Jiminez M, Forsyth LMG, Hall G, Stewart GA, Tan KAL, Hoyne GF, Lamb JR. Induction of tolerance via the respiratory mucosa. Int Arch Allergy Immunol. 116:1998;93-102.
43. Bauer L, Bohle B, Sahn-Schmid B, Wiedermann U, Daser A, Renz H, Kraft D, Ebner C. Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1. Clin Exp Immunol. 107:1997;536-541.
44. Cao Y, Yang M, Luo Z, Mohapatra SS. Vaccination with a multi-epitopic recombinant allergen induces specific immune deviation via T-cell anergy. Immunology. 90:1997;46-51.
45. Muller U, Akdis A, Fricker M, Akdis M, Blesken T, Betens F, Blaser K. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. of outstanding interest J Allerg Clin Immunol. 101:1998;747-754 This is the first convincing demonstration of clinically effective allergen immunotherapy using T cell epitope peptides. No allergic side-effects to the peptide treatment were experienced. Anergy induction and cytokine dysregulation were demonstrated.
46. Marcotte GV, Braun CM, Norman PS, Nicodemus CF, Kagey-Sobotka A, Lichtenstein LM, Essayan DM. Effects of peptide therapy on ex vivo T-cell responses. J Allerg Clin Immunol. 101:1998;506-513.
47. + T cells. J Immunol. 157:1996;2160-2165.
48. Fasler S, Aversa G, de Vries JE, Yssel H. Antagonistic peptides specifically inhibit proliferation, cytokine production, CD40L expression, and help for IgE synthesis by Der p 1-specific human T-cell clones. of special interest J Allerg Clin Immunol. 101:1998;521-530 This study shows that altered peptide ligands offer an alternative strategy for modulating the function of allergen-specific T cells by inhibiting proliferation, dysregulating cytokine secretion and abrogating B cell help for IgE synthesis.
49. Smith AM, Chapman MD, Taketomi EA, Platts-Mills TA, Sung SS. Recombinant allergens for immunotherapy: a Der p 2 variant with reduced IgE reactivity retains T-cell epitopes. J Allerg Clin Immunol. 101:1998;423-425.
50. h0 phenotype in vitro by induction of IL-12. Int Immunol. 9:1997;1867-1874.
51. Hetzel C, Janssen R, Ely SJ, Kristensen NM, Bunting K, Cooper JB, Lamb JR, Young DB, Thole JER. An epitope delivery system for use with recombinant mycobacteria. of special interest Infect Immun. 66:1998;3643-3648 This manuscript supports the use of mycobacteria as Th1-inducing delivery systems for vaccination using allergen peptides. Immunized mice generated peptide-specific IFN-γ responses.
52. Kim TS, DrKruyff RH, Rupper R, Maecker HT, Levy S, Umetsu DT. An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production. J Immunol. 158:1997;4137-4144.
53. Raz E, Tighe H, Sato Y, Corr M, Dudler JA, Roman M, Swain SL, Spiegelberg HL, Carson DA. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA. 93:1996;5141-5145.